Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Huiwen Jiang, Lin Liu, Tao Guo, et al.
Annals of Hematology (2019) Vol. 98, Iss. 7, pp. 1721-1732
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 204
Extrapulmonary complications of COVID‐19: A multisystem disease?
Kenneth I. Zheng, Gong Feng, Wen‐Yue Liu, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 1, pp. 323-335
Open Access | Times Cited: 187
T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis
Bahire Kalfaoglu, José Almeida‐Santos, Chanidapa Adele Tye, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 158
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
Craig W. Freyer, David L. Porter
Journal of Allergy and Clinical Immunology (2020) Vol. 146, Iss. 5, pp. 940-948
Open Access | Times Cited: 128
Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
Ying Zou, Hongying Guo, Yuyi Zhang, et al.
BioScience Trends (2020) Vol. 14, Iss. 4, pp. 285-289
Open Access | Times Cited: 117
Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial
Huiwen Jiang, Chenggong Li, Ping Yin, et al.
American Journal of Hematology (2019) Vol. 94, Iss. 10, pp. 1113-1122
Open Access | Times Cited: 114
Reactions Related to CAR-T Cell Therapy
Lele Miao, Zhengchao Zhang, Zhijian Ren, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 85
Clinical development of CAR T cell therapy in China: 2020 update
Jianshu Wei, Yelei Guo, Yao Wang, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 792-804
Open Access | Times Cited: 74
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, et al.
Cancer Medicine (2022) Vol. 12, Iss. 7, pp. 7844-7858
Open Access | Times Cited: 51
Dose–response correlation for CAR-T cells: a systematic review of clinical studies
Anand Rotte, Matthew J. Frigault, Ayub Ansari, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005678-e005678
Open Access | Times Cited: 46
Dose fractionation of CAR-T cells. A systematic review of clinical outcomes
Matthew J. Frigault, Anand Rotte, Ayub Ansari, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 27
Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?
Clara Benedetta Conti, Sonia Henchi, Giovanni Paolo Coppeta, et al.
European Journal of Internal Medicine (2020) Vol. 77, pp. 147-149
Open Access | Times Cited: 60
[Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19].
Hong Mei, Yi Hu
Zhonghua xueyexue zazhi/Zhōnghuá xuèyèxué zázhì (2020) Vol. 41, Iss. 3, pp. 185-191
Closed Access | Times Cited: 58
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Victor E. Tedesco, Chandra Mohan
The Journal of Immunology (2021) Vol. 206, Iss. 7, pp. 1561-1568
Open Access | Times Cited: 55
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Andrew Johnsrud, Juliana Craig, John H. Baird, et al.
Blood Advances (2021) Vol. 5, Iss. 21, pp. 4465-4475
Open Access | Times Cited: 53
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
Wenting Song, Mingzhi Zhang
Clinical Immunology (2020) Vol. 214, pp. 108382-108382
Closed Access | Times Cited: 51
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E. Levine, Stephan A. Grupp, Michael A. Pulsipher, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002287-e002287
Open Access | Times Cited: 48
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Wen Lei, Mixue Xie, Qi Jiang, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3912-3912
Open Access | Times Cited: 43
Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1
Rui Zhang, Qingxi Liu, Sa Zhou, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 21
Recognizing, defining, and managing CAR-T hematologic toxicities
Kai Rejeski, Marion Subklewe, Frederick L. Locke
Hematology (2023) Vol. 2023, Iss. 1, pp. 198-208
Closed Access | Times Cited: 19
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
Jennifer Jess, Bonnie Yates, Alina Dulau‐Florea, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e005898-e005898
Open Access | Times Cited: 18
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Yang Liu, Xingxing Jie, Nian Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies
Markus Perl, Konstantin Herfeld, Dennis Christoph Harrer, et al.
Haematologica (2024)
Open Access | Times Cited: 6
Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
Zhiqiang Song, Dingyuan Tu, Gusheng Tang, et al.
Haematologica (2023) Vol. 108, Iss. 8, pp. 2067-2079
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top